Related references
Note: Only part of the references are listed.IFN-y Signaling Sensitizes Melanoma Cells to BH3 Mimetics
Zizhen Ming et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2023)
Adjuvant Therapy of High-Risk (Stages IIC-IV) Malignant Melanoma in the Post Interferon-Alpha Era: A Systematic Review and Meta-Analysis
Konstantinos Christofyllakis et al.
FRONTIERS IN ONCOLOGY (2021)
Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression
Martina Proctor et al.
CANCERS (2021)
Targeted Therapy in Melanoma and Mechanisms of Resistance
Anna M. Czarnecka et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
A first-in-human phase I/II trial of SRA737 (a Chk1 Inhibitor) in subjects with advanced cancer.
Elizabeth Ruth Plummer et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine
Zay Yar Oo et al.
MOLECULAR ONCOLOGY (2019)
Mechanisms and Strategies to Overcome Resistance to Molecularly Targeted Therapy for Melanoma
Su Yin Lim et al.
CANCER (2017)
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms
Douglas B. Johnson et al.
EUROPEAN JOURNAL OF CANCER (2015)
Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor
Kevin B. Kim et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)